Monopar Therapeutics (MNPR) Cash from Investing Activities (2022 - 2025)

Monopar Therapeutics has disclosed Cash from Investing Activities across 4 years of filings, most recently posting -$62.2 million for Q4 2025.

• Cash from Investing Activities for Q4 2025 came in at -$62.2 million, down 333.72% year-over-year; the trailing twelve-month figure through Dec 2025 was -$63.5 million (down 342.54% YoY), and the FY2025 annual result was -$63.5 million, down 342.54% from the prior year.
• Cash from Investing Activities came in at -$62.2 million for Q4 2025 at Monopar Therapeutics, down from -$2.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $3.0 million in Q4 2023 to a low of -$62.2 million in Q4 2025.
• The 4-year median for Cash from Investing Activities is -$325828.0 (2025), against an average of -$6.0 million.
• Across the five-year window, Cash from Investing Activities tumbled 582.7% in 2024 and soared 49100.99% in 2025, its largest moves.
• Monopar Therapeutics' Cash from Investing Activities stood at -$4.9 million in 2022, then soared by 160.39% to $3.0 million in 2023, then sank by 582.7% to -$14.3 million in 2024, then tumbled by 333.72% to -$62.2 million in 2025.
• The last three Cash from Investing Activities figures came in at -$62.2 million (Q4 2025), -$2.1 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.